68% high-grade RFS reported at 12 months in BCG-unresponsive NMIBC study of HIVEC® with mitomycin C

Edward Bruce-White, Chief Executive Officer of Combat Medical, commented: “This study demonstrates HIVEC’s efficacy and tolerability in patients with BCG-unresponsive NMIBC and provides real-world evidence to support the potential of HIVEC as a highly effective bladder-preserving treatment option for patients who are unwilling or unfit to undergo radical cystectomy. Confirmation in our prospective HIVEC HEAT trial will establish HIVEC as a leading treatment option in this challenging patient population.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib